News

Julep Beauty hires chief delivery officer

BY Antoinette Alexander

SEATTLE — Omnichannel beauty brand Julep Beauty has hired Dwight Gaston as chief delivery officer, overseeing Julep's operations, customer service, fulfillment and product development teams.

Julep develops more than 300 new products each year for its Maven subscribers and e-commerce customers, and shipments are growing as more beauty enthusiasts discover Julep's range of toxin-free nail, skin care and makeup products, the company stated.

With more than 20 years of experience in the e-commerce and technology industries, Gaston joins Julep from online jewelry retailer Blue Nile, where he spent the past 15 years in executive roles. Most recently, he was Blue Nile's SVP of operations, and previously served as VP of operations and director of fulfillment operations. Earlier in his career, Gaston was a consultant with Bain & Co.

"After two decades in the e-commerce industry, I can honestly say I've never seen a more innovative consumer retail company than Julep," Gaston said. "Julep customers are fanatical about the brand, and the company uses social and mobile to connect with this passionate community to find out exactly which products resonate and which don't. Julep is on a tear and I'm excited to join the company to help build a distribution network that can scale with this tremendous growth."

"Julep is the first 'full-stack' beauty company, controlling every stage of the customer experience from product ideation, to testing and feedback, to manufacturing and fulfillment and delivery," said Jane Park, CEO and founder of Julep. "Operations and fulfillment are such a critical part of enabling the kind of unique customer experience we are creating, so Dwight's deep experience in building large-scale, e-commerce infrastructure will be incredibly important as we continue our rapid growth trajectory."
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Larabar introduces granola line

BY Ryan Chavis

MINNEAPOLIS — The makers of Larabar have announced the debut of Renola, a new type of granola made with nuts, fruits, seeds and spices, which the brand is billing as an alternative to classic granola.

"People love snacking, and we want them to feel good about their choices," said Julia Wing-Larson, marketing manager for Larabar. "Larabar has always been a great, gluten-free food, and we saw an opportunity in the marketplace to deliver a grain-free granola to consumers that is not only delicious, but full of whole and simple ingredients."  

Renola is available in three flavors: Cinnamon Nut, Cocoa Coconut and Berry. Consumers can purchase Larabar Renola at select Target stores, as well as a variety of grocery stores, for a suggested retail price of $1.79.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

FDA releases policy documents on compounding, including a draft interim guidance and a final guidance

BY Michael Johnsen

 
 
SILVER SPRING, Md. – The Food and Drug Administration on Tuesday issued several policy documents regarding compounding as part of the agency’s continuing effort to implement the compounding provisions of the Drug Quality and Security Act enacted in November 2013. 
 
The policy documents consist of a draft interim guidance, a proposed rule, a final guidance and two revised requests for nominations for the bulk drug substances lists. 
 
“Providing clarity to the compounding industry on the agency’s expectations for these unapproved drug products is a priority for the agency,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “These actions are essential next steps in providing the compounding industry with the appropriate tools to comply with the law and advancing the FDA’s efforts to continue protecting patients.”
 
The draft interim guidance outlines the FDA’s expectations regarding compliance with current good manufacturing practice requirements for facilities that compound and register with the FDA as outsourcing facilities under section 503B of the Federal Food, Drug and Cosmetic Act. The guidance focuses on cGMP requirements related to sterility assurance of sterile drug products and the general safety of compounded drug products.  
 
The final guidance is for individuals or pharmacies that intend to compound drugs under section 503A, now that the FD&C Act has been amended by the DQSA. The guidance generally restates the provisions of section 503A, describes the FDA’s interim policies with respect to specific provisions that require implementing regulations or other actions and contains a non-exhaustive list of potential enforcement actions against individuals or pharmacies that compound human drug products in violation of the FD&C Act.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES